Small Molecule PSMA-Targeted Alpha Therapy
小分子 PSMA 靶向阿尔法疗法
基本信息
- 批准号:9886363
- 负责人:
- 金额:$ 31.93万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-05-01 至 2024-01-31
- 项目状态:已结题
- 来源:
- 关键词:AblationAlpha Particle EmitterAlpha ParticlesAntigen TargetingBeta ParticleBiodistributionBiologicalBloodBone DiseasesCatabolismCharacteristicsChemistryClinical TrialsCohort StudiesDataDiscipline of Nuclear MedicineDiseaseDoseDrug KineticsEuropeEvaluationFOLH1 geneFrequenciesGalliumGoalsHumanImageImmunohistochemistryKnowledgeLabelLacrimal gland structureLeadLinear Energy TransferLutetiumMalignant NeoplasmsMalignant neoplasm of prostateMediatingMetabolismMetastatic Neoplasm to the BoneMolecularMulti-Institutional Clinical TrialMusPatientsPharmaceutical ChemistryPhasePhase I Clinical TrialsPositioning AttributePositron-Emission TomographyProceduresProstateQuality of lifeRadiation therapyRadioactivityRadiochemistryRadiolabeledRadiometryRadionuclide therapyRecommendationRegimenResistanceSalivary GlandsSpecimenStructureSurvival RateTestingTherapeutic Clinical TrialTherapeutic IndexTherapeutic StudiesTissuesToxic effectUrineWorkXenograft procedureadductanalogbasecastration resistant prostate cancercell killingclinical investigationdesigndosimetryexperiencehuman imaginghuman subjectimaging agentimaging studyin vivolipophilicitymeetingsmenmolecular imagingneoplastic cellprogramsradiotracerresistance mechanismresponsesmall moleculetargeted agenttargeted treatmenttreatment effecttumor
项目摘要
Project Summary
Despite the expanding array of new targeted agents to treat castration-resistant prostate cancer (CRPC), the
disease remains incurable with nearly half of men with this form of PC developing bone metastases at two years.
Metastatic bone disease carries a one-year survival rate of ~40%. Targeting the prostate-specific membrane
antigen (PSMA) with small molecules for imaging and radionuclide therapy (RT) of prostate and other cancers
has revitalized the field of nuclear medicine. Novartis has recently acquired [177Lu]R2, developed by us, and
[177Lu]PSMA-617, two PSMA-targeted RT labeled with the β-particle emitter 177Lu that are in multi-center clinical
trials. In Europe, there have been preliminary trials using the α-particle emitting agent [225Ac]PSMA-617 that
have shown substantial treatment effects, even in patients that became resistant to the corresponding 177Lu-
labeled compound. However, these encouraging responses to targeted α-particle RT (TAT) often came at the
expense of immediate ablation of the salivary and lacrimal glands, with long-term toxicities unknown. Accordingly,
despite widespread efforts, translational RT for PC is at a crucial stage, having yet to identify an agent that
provides durable responses without compromising quality of life. The approach that we shall take in this
competing renewal is to extend our basic work focusing on 211At, which emits a single α-particle per decay, to a
low-dose, pharmacokinetic clinical trial. We hypothesize that 211At will provide an intermediate between the
minimally toxic, but less effective 177Lu and the more powerful but potentially damaging 225Ac, which emits a total
of four α-particles per decay that are difficult to control in vivo and promote the aforementioned toxicity. Our goal
is to have an agent with an optimal therapeutic index by combining the high linear energy transfer (LET) tumor
cell kill of 211At with greater control of toxicity through molecular design for salutary pharmacokinetics and dosing
strategies. Preliminary in vivo data with our lead 211At-labeled compound, [211At]VK-02-90-Lu, indicates much
lower off-target toxicity than for a related 225Ac-labeled adduct, confirmed by immunohistochemistry, with similar
survival characteristics. The current program is intended to provide the experimental rationale and data for an
IND-enabling therapeutic study.
项目概要
尽管治疗去势抵抗性前列腺癌(CRPC)的新靶向药物不断增多,但
这种疾病仍然无法治愈,近一半患有这种 PC 的男性在两年内会发生骨转移。
转移性骨病的一年生存率约为 40%。靶向前列腺特异性膜
抗原 (PSMA) 与小分子,用于前列腺癌和其他癌症的成像和放射性核素治疗 (RT)
重振了核医学领域。诺华最近收购了我们开发的[177Lu]R2,并且
[177Lu]PSMA-617,两种β粒子发射体177Lu标记的PSMA靶向RT,处于多中心临床
试验。在欧洲,已经进行了使用α粒子发射剂[225Ac]PSMA-617的初步试验,
即使在对相应 177Lu- 产生耐药性的患者中,也显示出显着的治疗效果
标记的化合物。然而,这些对靶向 α 粒子 RT (TAT) 的令人鼓舞的反应往往是在
立即消融唾液腺和泪腺的费用,长期毒性未知。因此,
尽管做出了广泛的努力,PC 的转化 RT 仍处于关键阶段,尚未确定一种药物可以
提供持久的反应而不影响生活质量。我们在这方面将采取的方法
竞争性的更新是将我们专注于 211At 的基础工作扩展至
低剂量、药代动力学临床试验。我们假设 211At 将提供介于
毒性最小但效果较差的 177Lu 和毒性更强但具有潜在破坏性的 225Ac,其排放总量
每次衰变有四个 α 粒子,这在体内难以控制并促进上述毒性。我们的目标
就是通过结合高线性能量转移(LET)肿瘤来获得具有最佳治疗指数的药剂
通过分子设计实现有益的药代动力学和剂量,杀死 211At 细胞并更好地控制毒性
策略。我们的先导 211At 标记化合物 [211At]VK-02-90-Lu 的初步体内数据表明很多
经免疫组织化学证实,与相关 225Ac 标记的加合物相比,脱靶毒性较低,具有相似的效果
生存特征。当前的计划旨在提供实验原理和数据
支持 IND 的治疗研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARTIN G POMPER其他文献
MARTIN G POMPER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARTIN G POMPER', 18)}}的其他基金
Translational imaging biomarkers of the tumor microenvironment in early prostate cancer
早期前列腺癌肿瘤微环境的转化成像生物标志物
- 批准号:
10698133 - 财政年份:2022
- 资助金额:
$ 31.93万 - 项目类别:
Translational imaging biomarkers of the tumor microenvironment in early prostate cancer
早期前列腺癌肿瘤微环境的转化成像生物标志物
- 批准号:
10518916 - 财政年份:2022
- 资助金额:
$ 31.93万 - 项目类别:
Resource for Molecular Imaging Agents in Precision Medicine
精准医学分子成像剂资源
- 批准号:
10226206 - 财政年份:2017
- 资助金额:
$ 31.93万 - 项目类别:
Administration - Resource for Molecular Imaging Agents in Precision Medicine
管理 - 精准医学中分子成像剂的资源
- 批准号:
10226207 - 财政年份:2017
- 资助金额:
$ 31.93万 - 项目类别:
Training/Dissemination - Resource for Molecular Imaging Agents in Precision Medicine
培训/传播 - 精准医学分子成像剂资源
- 批准号:
10226214 - 财政年份:2017
- 资助金额:
$ 31.93万 - 项目类别:
Imaging Agents for Inflammatory Components of Malignancy
恶性肿瘤炎症成分的显像剂
- 批准号:
10226210 - 财政年份:2017
- 资助金额:
$ 31.93万 - 项目类别:
相似海外基金
Alpha-Particle Emitter Radiopharmaceutical Therapy for Liver Cancer
肝癌的α粒子发射放射性药物治疗
- 批准号:
10531240 - 财政年份:2019
- 资助金额:
$ 31.93万 - 项目类别:
Alpha-Particle Emitter Peptide Receptor Targeted Radionuclide Therapy for Neuroendocrine Tumors
α粒子发射肽受体靶向放射性核素治疗神经内分泌肿瘤
- 批准号:
10673599 - 财政年份:2019
- 资助金额:
$ 31.93万 - 项目类别:
Alpha-Particle Emitter Peptide Receptor Targeted Radionuclide Therapy for Neuroendocrine Tumors
α粒子发射肽受体靶向放射性核素治疗神经内分泌肿瘤
- 批准号:
10152579 - 财政年份:2019
- 资助金额:
$ 31.93万 - 项目类别:
Alpha-Particle Emitter Radiopharmaceutical Therapy for Liver Cancer
肝癌的α粒子发射放射性药物治疗
- 批准号:
10305102 - 财政年份:2019
- 资助金额:
$ 31.93万 - 项目类别:
Alpha-Particle Emitter Radiopharmaceutical Therapy for Liver Cancer
肝癌的α粒子发射放射性药物治疗
- 批准号:
10394421 - 财政年份:2019
- 资助金额:
$ 31.93万 - 项目类别:
Alpha-Particle Emitter Radiopharmaceutical Therapy for Liver Cancer
肝癌的α粒子发射放射性药物治疗
- 批准号:
9884219 - 财政年份:2019
- 资助金额:
$ 31.93万 - 项目类别:
Alpha-Particle Emitter Peptide Receptor Targeted Radionuclide Therapy for Neuroendocrine Tumors
α粒子发射肽受体靶向放射性核素治疗神经内分泌肿瘤
- 批准号:
10396517 - 财政年份:2019
- 资助金额:
$ 31.93万 - 项目类别:
Targeted Alpha-Particle Emitter Therapy of Metastases
转移瘤的靶向阿尔法粒子发射治疗
- 批准号:
7156165 - 财政年份:2005
- 资助金额:
$ 31.93万 - 项目类别:
Targeted Alpha-Particle Emitter Therapy of Metastases
转移瘤的靶向阿尔法粒子发射治疗
- 批准号:
7033111 - 财政年份:2005
- 资助金额:
$ 31.93万 - 项目类别:
Targeted Alpha-Particle Emitter Therapy of Metastases
转移瘤的靶向阿尔法粒子发射治疗
- 批准号:
7317817 - 财政年份:2005
- 资助金额:
$ 31.93万 - 项目类别: